Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

The FDA warns GLP-1 weight loss drug users of aspiration risks during anaesthesia Learn what this update means and how to ...

A DAD died after taking a weight loss jab for just a few weeks. Tim Ramsay, from South Australia, wanted to shed some pounds so he could confidently walk his daughter down the aisle. The ...

Drugs such as Wegovy, Ozempic, and Saxenda have quickly become household names. But are these weight loss medications right ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Although Ozempic and Victoza aren’t currently approved for weight management, other diabetes drugs are used for this purpose. For example, Saxenda (liraglutide), which has the same active drug ...

Saxenda contains the active ingredient liraglutide, which belongs to the class of medications glucagon-like peptide-1 (GLP-1) agonists. Other GLP-1 agonists include Ozempic and Wegovy. It is ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic, Wegovy, Rybelsus, and Saxenda. The main compound that Ozempic, Wegovy, and Rybelsus ...